Lumee Oxygen Platform
Commercial- Indications
- Peripheral artery disease, Diabetic ulcers, Pressure sores
Company intelligence / Profile preview
Profusa has developed a CE-marked tissue-integrating hydrogel biosensor system—Lumee Oxygen Platform—for continuous real-time measurement of tissue oxygenation. The device enables long-term monitoring without the foreign body response typical of metal/electronic implants. Clinical studies have shown promise for use in peripheral artery disease and chronic wound management. A second product—a continuous glucose monitor—is currently under clinical development. The company’s technology platform allows expansion to additional analytes and indications.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Profusa.